NCT06631300View on ClinicalTrials.gov

A Randomized, Placebo-controlled Trial of Prednisone in Refractory Restless Legs Syndrome: a Pilot Study

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

June 1, 2025

Study Completion Date

December 31, 2025

Conditions
Restless Legs Syndrome
Interventions
DRUG

Prednisone

A prednisone taper will be given to the subjects as follows: prednisone 40mg for 3 days, prednisone 30mg for 3 days, prednisone 20mg for 3 days, prednisone 10mg for 3 days, prednisone 5mg for 3 days, then off for a total of 15 days.

DRUG

Placebo

A placebo taper will be given to match the same number of pills administered in each stage of the prednisone taper.

All Listed Sponsors
lead

Scripps Health

OTHER